-=Novan (NOVN) reports Phase 3 Trial of SB206 met primary endpoint

• Molluscum is a common, contagious skin infection caused by the molluscipoxvirus. 

Novan reports Phase 3 Trial of SB206 met primary endpoint

Co announced positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum. Molluscum is a common, contagious skin infection caused by the molluscipoxvirus, affecting approximately six million people in the U.S. annually, with the greatest incidence in children aged one to 14 years.

Consistent with results from the Company's Phase 2 and earlier Phase 3 studies, SB206 was found to be safe and well tolerated. No treatment-related serious adverse events were reported.

Novan intends to submit New Drug Application no later than the third quarter of 2022.